Active Not RecruitingNCT07047651

Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.

This study is active but not recruiting. It focuses on schizophrenia and currently lists study information in Greece.

SchizophreniaOtherFrom 18 Years to 65 Years

In plain English

Key information made simple

This study is looking at whether Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram), can help people with Treatment Resistant Schizophrenia or Treatment Resistant bipolarity. Participants take part in Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram), and complete follow-up assessments. Taking part may give some people access to Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, but direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests in-person participation through a research setting, with sites including Private practice of Dr S Rakitzi and Dr P Georgila ILISION 34 15771 ATHENS GREECE. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually matching the main diagnosis, while common reasons not to take part include active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means the approach is being followed in broader real-world use.

Public study data

Key study information

Condition: Treatment Resistant Schizophrenia; Treatment Resistant Bipolarity
Study status: Active Not Recruiting
Sponsor / lead affiliation: Dr. Stavroula Rakitzi
Location / country: Greece
Registry: ClinicalTrials.gov

Why this study may matter

This study may matter because it adds public evidence around schizophrenia. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

Before joining

Questions to ask before joining

What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Study reference: NCT07047651. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.

In practice

For you

Taking part may help improve understanding of your condition.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in Greece.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

Study clarity

Things to check before joining

Sponsor: Dr. Stavroula Rakitzi
Sponsor type: Individual investigator
Main activity: observational follow-up
Intervention: Not available
Time commitment: multiple visits or assessments
Study phase: Not available
Enrollment: Not available
Recruitment status: Active Not Recruiting
Source: Official registry link

FAQ

Questions about this study

What is Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.?

This study is exploring observational follow-up for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Dr. Stavroula Rakitzi. Based on the sponsor name or official registry information, it appears to be an individual investigator. You should verify the details in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve observational follow-up, study visits, and assessments. The time commitment is multiple visits or assessments. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.